Eliem Therapeutics Basic EPS 2021-2024 | CLYM
Eliem Therapeutics basic eps from 2021 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| Eliem Therapeutics Annual Basic EPS |
| 2023 |
$-1.30 |
| 2022 |
$-1.72 |
| 2021 |
$-4.24 |
| 2020 |
$-10.49 |
| Eliem Therapeutics Quarterly Basic EPS |
| 2024-06-30 |
$-1.81 |
| 2024-03-31 |
$-0.06 |
| 2023-12-31 |
$-0.12 |
| 2023-09-30 |
$-0.15 |
| 2023-06-30 |
$-0.19 |
| 2023-03-31 |
$-0.84 |
| 2022-12-31 |
$-0.29 |
| 2022-09-30 |
$-0.37 |
| 2022-06-30 |
$-0.56 |
| 2022-03-31 |
$-0.50 |
| 2021-12-31 |
$5.27 |
| 2021-09-30 |
$-0.70 |
| 2021-06-30 |
$-3.11 |
| 2021-03-31 |
$-5.70 |
| 2020-12-31 |
|
| 2020-09-30 |
$-1.46 |
| 2020-06-30 |
$-1.12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
